The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques
Open accessAbstract
Immunity from reinfection: One of the many open questions about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is whether an individual who has cleared the virus can be infected a second time and get sick. Chandrashekar et al. and Deng et al. generated rhesus macaque models of SARS-CoV-2 infection and tested whether natural SARS-CoV-2 infection could result in immunity to viral rechallenge. They found that animals indeed developed immune responses that protected against a second infection. Although there are differences between SARS-CoV-2 infection in macaques and in humans, these findings have key implications for public health and economic initiatives if validated in human studies. Science , this issue p. 812 , p. 818
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Initial studies in macaques showed that a primary infection with SARS-CoV-2 protects against subsequent viral challenge for at least 28–35 days, with re-exposure driving memory immune responses that included boosting of binding and neutralizing antibody levels as well as of IFNγ secretion by T cells46,47.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [46]
In the citing paper
“Preexisting immunity to SARS-CoV-2 is associated with protection against reinfection in humans (9–11) and in nonhuman primates (12, 13).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [13]
In the citing paper
“Animals infected with SARS-CoV-2 were protected from a high dose re-challenge with SARS-CoV-2 1 month later, and protection was associated with neutralizing antibodies”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Deng et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
To, K. K., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C., Cai, J., Chan, J. M., Chik, T. S., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,045
Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614
Positive RT-PCR test results in patients recovered from COVID-19
Lan, L., Xu, D., Ye, G., Xia, C., Wang, S., Li, Y., & Xu, H. (2020) · JAMA · doi:10.1001/jama.2020.2783 · Cited by 1,251
Self-citationThe pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., Wei, Q., Yu, P., Xu, Y., Qi, F., et al. (2020) · Nature · doi:10.1038/s41586-020-2312-y · Cited by 1,126
Self-citationComparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model
Rockx, B., Kuiken, T., Herfst, S., Bestebroer, T., Lamers, M. M., Oude Munnink, B. B., de Meulder, D., van Amerongen, G., van den Brand, J., Okba, N. M. A., et al. (2020) · Science · doi:10.1126/science.abb7314 · Cited by 901
SARS-CoV-2 infection protects against rechallenge in rhesus macaques
Chandrashekar, A., Liu, J., Martinot, A. J., McMahan, K., Mercado, N. B., Peter, L., Tostanoski, L. H., Yu, J., Maliga, Z., Nekorchuk, M., et al. (2020) · Science · doi:10.1126/science.abc4776 · Cited by 816
Self-citationWu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y., Zhang, Y., Xun, J., Lu, L., et al. (2020) · doi:10.1101/2020.03.30.20047365 · Cited by 754
Self-citationRespiratory disease in rhesus macaques inoculated with SARS-CoV-2
Munster, V. J., Feldmann, F., Williamson, B. N., van Doremalen, N., Pérez-Pérez, L., Schulz, J., Meade-White, K., Okumura, A., Callison, J., Brumbaugh, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2324-7 · Cited by 720
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
Williamson, B. N., Feldmann, F., Schwarz, B. H., Meade-White, K. D., Porter, D., Schulz, J. E., van Doremalen, N., Leighton, I. A., Yinda, C. K., Pérez-Pérez, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2423-5 · Cited by 696
Flagged first, then by citations
Cited by
Sorted by citations
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
SARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098
Adaptive immunity to SARS-CoV-2 and COVID-19
Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Metadata
- Authors
- Deng, W., Bao, L., Liu, J., Xiao, C., Liu, J., Xue, J., Lv, Q., Qi, F., Gao, H., Yu, P., Xu, Y., Qu, Y., Li, F., Xiang, Z., Yu, H., Gong, S., Liu, M., Wang, G., Wang, S., Song, Z., Liu, Y., Zhao, W., Han, Y., Zhao, L., Liu, X., Wei, Q., & Qin, C.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Capital Medical University (CN)
- Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, NHC Key Laboratory of Human Disease Comparative Medicine, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China.
- Corresponding author
- Deng, Wei
- Bao, Linlin
- Liu, Jiangning
- Xiao, Chong
- Liu, Jiayi
- Xue, Jing
- Lv, Qi
- Qin, Chuan
- ORCID
- Venue
- Science
- Published
- 2020-08-14
- Volume
- 369
- Issue
- 6505
- Pages
- 818-823
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7402625
- OpenAlex
- W3038698073
- Cited by
- 440
- References
- 16
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 18 · 2023: 41 · 2022: 84 · 2021: 176 · 2020: 104
- FWCI
- 13.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National key research and development project of China (2016YFD0500304)
- National Mega projects of China for Major Infectious Diseases (2017ZX10304402)
- CAMS Initiative for Innovative Medicine of China (2016-I2M-2-006)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, reinfection, rhesus monkeys, primary infection, drug rechallenge, neutralizing antibodies, humoral immunity, cell-mediated immunity, interstitial lung disease, viral dissemination, convalescence
- MeSH terms
- Betacoronavirus, Host Microbial Interactions, COVID-19, SARS-CoV-2, Animals, Antibodies, Viral, Anal Canal, Disease Models, Animal, Immunity, Cellular, Lung, Macaca mulatta, Nasopharynx, Pneumonia, Viral, Recurrence, Virus Replication, B-Lymphocyte Subsets, T-Lymphocyte Subsets, Lung Diseases, Interstitial, Coronavirus Infections, Viral Load, Immunity, Humoral, Antibodies, Neutralizing, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
